Revenue was $1.78M, down from $2.77M YoY, driven by reduced licensing income. Net loss widened to $15.43M due to increased R&D spending on bosakitug and ATI-052 trials. Operating loss was $18.41M. Cash, cash equivalents, and marketable securities totaled $180.89M, providing runway into H2 2028.

Aclaris Therapeutics reported a net loss of $15.1 million for the first quarter of 2025, an improvement from the $16.9 million loss in Q1 2024. Total revenue for the quarter was $1.5 million. The company ended the quarter with $190.5 million in cash, cash equivalents, and marketable securities, extending its cash runway through the first half of 2028.

Aclaris Therapeutics reported Q4 2024 financial results, featuring a revenue of $9.2 million and a net loss of $96.6 million. The company highlighted its cash runway extending into 2028 and progress in its clinical development programs.

Aclaris Therapeutics reported a decrease in revenue for the third quarter of 2024, primarily driven by lower milestone payments compared to the previous year. The company highlighted the dosing of the first patient in the Phase 2a trial of ATI-2138 for atopic dermatitis and anticipates top-line data in the first half of 2025.

Aclaris Therapeutics reported a net loss of $11.0 million and total revenue of $2.8 million for the second quarter of 2024. The company's cash, cash equivalents, and marketable securities totaled $149.9 million as of June 30, 2024.

Aclaris Therapeutics reported a net loss of $16.9 million and total revenue of $2.4 million for the first quarter of 2024. The company is progressing ATI-2138 into a Phase 2a trial for atopic dermatitis and seeking a partner for lepzacitinib. They had cash, cash equivalents, and marketable securities of $161.4 million as of March 31, 2024.

Aclaris Therapeutics reported a net loss of $1.5 million for the fourth quarter of 2023, compared to a net loss of $27.6 million for the fourth quarter of 2022. Total revenue was $17.6 million for the fourth quarter of 2023, compared to $7.8 million for the fourth quarter of 2022. As of December 31, 2023, Aclaris had aggregate cash, cash equivalents and marketable securities of $181.9 million.

Aclaris Therapeutics reported a net loss of $29.3 million for Q3 2023, compared to a net loss of $20.0 million for Q3 2022. Total revenue was $9.3 million, down from $19.0 million in the prior year, primarily due to a one-time upfront payment received in 2022. The company is focused on advancing its clinical development programs, with topline data expected for zunsemetinib in rheumatoid arthritis this month and ATI-1777 in atopic dermatitis around year-end 2023.

Aclaris Therapeutics reported a net loss of $29.6 million on total revenue of $1.9 million for the second quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $210.8 million as of June 30, 2023, which is expected to fund operations through the end of 2025.

Aclaris Therapeutics reported a net loss of $28.2 million on total revenue of $2.5 million for the first quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $204.4 million as of March 31, 2023, and anticipates funding operations through the end of 2025.

Aclaris Therapeutics reported a net loss of $27.6 million for the fourth quarter of 2022, compared to a net loss of $22.8 million for the fourth quarter of 2021. Total revenue was $7.8 million for the fourth quarter of 2022, compared to $1.5 million for the fourth quarter of 2021.

Aclaris Therapeutics reported total revenue of $19.0 million for the third quarter of 2022, compared to $1.7 million for the third quarter of 2021. The increase was driven by $17.9 million of licensing revenue, including $17.6 million from a non-exclusive patent license agreement with Lilly. Net loss was $20.0 million for the third quarter of 2022, compared to $21.1 million for the third quarter of 2021.